MARKET

NBSE

NBSE

Neubase Therapeutics Inc
NASDAQ
0.1825
+0.0028
+1.56%
Closed 19:34 06/05 EDT
OPEN
0.1656
PREV CLOSE
0.1797
HIGH
0.1825
LOW
0.1656
VOLUME
120.06K
TURNOVER
--
52 WEEK HIGH
1.450
52 WEEK LOW
0.1206
MARKET CAP
6.17M
P/E (TTM)
-0.2421
1D
5D
1M
3M
1Y
5Y
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga · 5d ago
NeuBase Releases Promising Preclinical Data From Stealth Editors To Achieve Gene Editing
Benzinga · 05/22 16:41
BRIEF-Neubase Announces Positive Preclinical Data Supporting The Capabilities Of Stealth Editors
Reuters · 05/22 11:43
Neubase Therapeutics Inc: Current report
Press release · 05/22 11:08
BRIEF-Neubase Announces Formation Of Gene Editing Advisory Board
Reuters · 05/16 21:20
NeuBase Therapeutics GAAP EPS of -$0.12 misses by $0.02
Seeking Alpha · 05/11 21:22
BRIEF-Neubase Reports Business Update And Financial Results For The First Quarter Of 2023
Reuters · 05/11 21:09
BRIEF-Neubase Therapeutics Board Approved A Change In Co's Fiscal Year
Reuters · 04/24 22:08
More
About NBSE
NeuBase Therapeutics, Inc. is a preclinical-stage biopharmaceutical company. The Company is developing a modular peptide-nucleic acid (PNA) antisense oligo (PATrOL) platform to address genetic diseases. The PATrOL-enabled anti-gene therapies are designed to improve upon current genetic medicine strategies by combining the advantages of synthetic approaches with the precision of antisense technologies. Its programs are NT-0100 in HD, NT-0200 in Myotonic Dystrophy Type 1 (DM1) and NT-0300 in KRAS-driven cancers. The NT-0100 program is a PATrOL-enabled therapeutic program being developed to target the mutant expansion in the HD messenger ribonucleic acid (mRNA). The NT-0200 program is a PATrOL-enabled therapeutic program being developed to target the mutant expansion in the DM1 disease mRNA. The NT-0300 program is a PATrOL-enabled therapeutic program being developed to target the mutated KRAS gene.

Webull offers kinds of Neubase Therapeutics Inc stock information, including NASDAQ:NBSE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NBSE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NBSE stock methods without spending real money on the virtual paper trading platform.